Dr. Gregory Lee was professor at University of British Columbia in Vancouver, Canada until 2012. He received his M.Sc. and PhD in chemistry from California Institute of Technology Pasadena, CA in 1972. Previously, he also served as Research Assistant Professor at University of North Carolina, Department of Biochemistry, Chapel Hill, N.C., U.S.A.
Dr. Gregory Lee received patents like Humanized antibodies Carbohydrate hapten-based Anti-cancer vaccines and Antibody Drugs Humanized forms of monoclonal antibodies to human GnRH Receptor etc... He has special interest in General Ligand Affinity Chromatography, Immobilized Enzymes, Biochemical Genetics of Mouse Enzymes, Applications of Hybridoma Technology Research and Development of Rapid Immunodiagnostic Tests, Research and Development of Antibody-Based Anti-Cancer Drugs. He has membership in editorial boards and also has national and international publications around 190.
Dr. Gregory Lee’s major research interest is in the field of biotechnology. He has generated numerous monoclonal antibodies for immunodiagnostic and therapeutic applications, including the early pregnancy detection, ovulation, myocardial infarction and cancer.
During the last decade, he has been focused on research and development of the Monoclonal antibody-based anti-cancer drugs (noticeably RP215 and GHR106) for Immunotherapy of human cancer.
